Novartis | NOVN - PE Price to Earnings


Novartis reported 20.17 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
AbbVie 23.03 1 Mar/2026
Alcon AG 36.42 1.77 Mar/2026
Almirall 79.43 0.3 Dec/2025
Amgen 19.84 5.47 Mar/2026
AstraZeneca 29.59 2.3 Mar/2026
Bayer 3.4 8.75 Mar/2026
Biogen 13.7 0.32 Mar/2026
Bristol-Myers Squibb 9.08 0.2 Mar/2026
Eli Lilly 40.27 0.06 Mar/2026
Fresenius 15.18 0.63 Dec/2025
Fresenius Medical Care 6.64 2.07 Mar/2026
Genmab 17.14 4.39 Dec/2025
Gilead Sciences 17.7 2.07 Mar/2026
GlaxoSmithKline 14.87 3.72 Mar/2026
GRIFOLS 10.98 5.83 Mar/2026
Hikma Pharmaceutical 10.43 3.72 Dec/2025
J&J 24.53 0.91 Mar/2026
Lakefront Biotherapeutics 2.54 0.6 Mar/2026
Lonza 34.34 2.58 Dec/2025
Merck 12.74 7.82 Mar/2026
Merck 16.52 2.6 Mar/2026
Novartis 20.17 2.32 Mar/2026
Novartis 17.79 1.74 Dec/2025
Novo Nordisk 12.78 0.01 Dec/2025
Orion 18.52 10.02 Mar/2026
Pfizer 9.32 5.16 Mar/2026
Philips 14.32 1.33 Mar/2026
Recordati 17.66 7.44 Mar/2026
Regeneron Pharmaceuticals 25.14 7.03 Mar/2026
Roche Holding 16.09 3.51 Dec/2025
Sanofi 11.84 0.14 Mar/2026
UCB 29.7 5.52 Dec/2025